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abstract: Prostanoids are well-described primary mediators of inﬂammatory processes and are essential for the normal physiological
function of the female reproductive system. The aim of this study was to determine the temporal expression of the prostanoid biosynthetic
enzymes (PTGS1, PTGS2, PTGES, PTGES2, PTGES3, AKR1B1, AKR1C3, CBR1, HPGDS, PTGDS, PTGIS, TBXAS1 and HPGD) and the
prostanoid receptors (PTGER1, PTGER2, PTGER3, PTGER4, PTGFR, PTGDR, GPR44, PTGIR and TBXA2R) in the human endometrium
throughout the menstrual cycle. The analysis identiﬁed PTGFR to have a distinct expression proﬁle compared with other components of the
prostanoid system, as expression is maximal during the proliferative phase. Immunohistochemical analysis for PTGER1 suggests a dual func-
tion for this receptor depending on its temporal (proliferative versus secretory) and spatial (nuclear versus cell membrane) expression. The
expression proﬁles of the PGF2a synthases identiﬁed AKR1B1 and CBR1 as the likely regulators of PGF2a production during the menstrual
phase. Immunohistochemical analysis for AKR1B1, CBR1 and AKR1C3 suggest expression to be in the glandular epithelium and vasculature.
This study represents the ﬁrst comprehensive analysis of the components of prostanoid biosynthetic and signalling pathway in the human
endometrium. The expression proﬁles described have the potential to identify speciﬁc prostanoid components that may be dysregulated
in inﬂammatory-associated disorders of the endometrium.
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Introduction
The prostanoids are part of a family of biologically active lipids derived
from arachidonic acid which include the prostaglandins, prostacyclins
and thromboxanes. Prostanoids are well-described primary mediators
in pathological conditions such as inﬂammation, hypertension and
cancer but are also essential for normal physiological function such
as in the female reproductive system (Loftin et al., 2002). The impor-
tance of prostaglandins in the female reproductive tract is well docu-
mented in the mouse where targeted disruption of prostaglandin
endoperoxidase synthase 1 or 2 (PTGS1 and PTGS2, previously
known as COX1 and COX2) genes result in reduced reproductive
efﬁciency (Lim et al., 1997; Gross et al., 1998). In humans, dysregu-
lated endometrial prostanoid production has been described as a con-
tributing factor in menstrual cycle disorders, infertility and uterine
malignancies (Jabbour et al., 2006; 2009; Achache et al., 2010). Non-
steroidal anti-inﬂammatory drugs (NSAIDS) are well documented to
inhibit prostanoid synthesis and are prominent analgesic/anti-
inﬂammatory/antipyretic medication. However, a major drawback is
that they target the early steps of biosynthesis thus blocking all pros-
tanoids. Therefore, targeting of selective prostanoid synthases or
receptors seem a logical progression in the development of new thera-
peutic strategies.
Prostanoids are not stored within cells, but are synthesized as
required in response to stimuli. The ﬁrst step in their synthesis is
the release of arachidonic acid from the cellular phospholipids, by
the action of the enzyme phospholipase A2. Arachidonic acid is con-
verted by one of two related enzymes, PTGS1 and PTGS2, to form
ﬁrstly prostaglandin PGG2 and subsequently reduced to prostaglandin
PGH2. PGH2 is an unstable intermediate from which all other prosta-
noids are derived by a variety of different prostanoid synthases and
isomerases (reviewed in Watanabe, 2002; Fortier et al., 2008; sum-
marized in Fig. 1). Thus PGH2 is converted to PGD2, PGI2, TXA2
PGE2 and PGF2a by prostaglandin D synthases (PTGDS and
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(TBXAS1), prostaglandin E synthases and prostaglandin F synthases,
respectively. A number of distinct forms of prostaglandin E synthase
exist, a membrane-bound type 1 (PTGES), a type 2 (PTGES2) which
has various isoforms and a cytosolic (PTGES3) synthase. PGF2a is syn-
thesized via various routes, although not all routes of synthesis have
been demonstrated in human endometrial cells. PGF2a can be pro-
duced directly from PGH2 by aldo-keto reductase family 1 members
B1 and C3 (AKR1B1 and AKR1C3). Alternatively, it can be syn-
thesized via PGE2 by the action of the enzymes carbonyl reductase
1 (CBR1), AKR1C1 and AKR1C2 (Terada et al., 2001; Dozier et al.,
2008) or by reduction of PGD2 by AKR1C3. Prostanoids such as
PGI2 and TXA2 are deactivated spontaneously before they are
exported into the circulation as inactive metabolites. Other prosta-
noids, such as PGE2 and PGF2a, can be actively metabolized by
hydroxyprostaglandin dehydrogenase (HPGD) or CBR1 into keto-
prostanoids (Casey et al., 1980; Terada et al., 2001).
Following biosynthesis, prostanoids exert their function through G
protein coupled receptors. The receptors have preferential binding
to speciﬁc ligands; PTGER1–4 for PGE2, PTGFR for PGF2a,
PTGDR1 and GPR44 for PGD2, PTGIR for PGI2 and TBXA2R for
TXA2 (Abramovitz et al., 2000). Prostanoids may also exert their
function through nuclear receptors such as binding of PGI2 to peroxi-
some proliferator-activated receptor (PPARd)( Dussault and Forman,
2000).
The aim of this study was to identify the temporal expression proﬁle
of the prostanoid system in the human endometrium across the men-
strual cycle. To our knowledge this is the ﬁrst quantitative and fully
comprehensive analysis of the prostanoid system across the menstrual
cycle in the human endometrium. The data are discussed in relation to
key inﬂammatory events during the menstrual cycle.
Materials and Methods
Patients and tissue collection
Endometrial biopsies were obtained from women (age range 21–39 years)
with regular menstrual cycles who had not received hormonal preparation
in the 3 months preceding biopsy collection, and dated according to
Noyes criteria (Noyes et al., 1975) by a pathologist. Circulating estradiol
and progesterone concentrations were measured and were consistent
with the histological assessment. Ethical approval was obtained from
Lothian research ethics committee and written informed patient consent
obtained before tissue collection.
Quantitative RT–PCR
RNA was extracted with TRI-reagent (Thermo Scientiﬁc, Cramlington,
UK) following manufacturers guidelines using phase lock tubes (Eppendorf,
Cambridge, UK). RNA samples were reverse transcribed using MultiScribe
(Applied Biosystems, Foster City, CA, USA) primed with random hexam-
ers according to the manufacturer’s instructions. PCR reactions were
carried out using an ABI Prism 7500 (Applied Biosystems). Primer and
FAM (6-carboxyﬂuorescein)-labelled probe sequences are shown in
Table I. Multiple transcript variants have been reported for human
PTGFR (Liang et al., 2008). However, only the full length receptor was
detected in the human endometrium in this study. Multiple transcript var-
iants have been described for PTGER3 (Kotani et al., 1997), TBXA2R
(Miggin and Kinsella, 1998) and TBXAS1 (Swanson et al., 1992). The
primers utilized in this study did not distinguish between these isoforms.
Pre-validated primers and probes were purchased for AKR1B1,
PTGES3, HPGDS and GPR44 (Assay-on-Demand, Applied Biosystems).
Primer-only ampliﬁcation products were detected using SYBR Green
(Applied Biosystems) incorporation during the PCR reaction. Gene
expression was normalized to 18S ribosomal RNA (Applied Biosystems)
as an internal standard. Results are expressed as relative to a standard
(pooled endometrial tissue cDNA) included in all reactions.
Immunohistochemistry
Five micrometres of parafﬁn-embedded sections were de-waxed and rehy-
drated through graded alcohols before antigen retrieval was carried out
using 0.01 M citrate phosphate buffer in a pressure cooker for 5 min at
maximum pressure. After release of pressure, the sections were incubated
for a further 21 min before endogenous peroxidase activity was blocked by
5 min incubation in 3% solution of hydrogen peroxide: methanol. Immuno-
histochemistry was performed using an automated Visions Biosytems
‘Bond’ Immunohistochemistry system (Bond, CA, USA). Sections were
incubated for 120 min with primary antibodies such as mouse anti-
AKR1C3 (1:5000; A6229; Sigma, Dorset, UK); rabbit anti-AKR1B1
(1:50; Ab71405; Abcam, Cambridge, UK); goat anti-CBR1 (1:500;
Ab4148; Abcam); rabbit anti-PTGDR (1:100; 101640; Cayman Chemicals,
Ann Arbor, MI, USA); rabbit anti-PTGER1 (1:500; 101740; Cayman
Chemicals) and a corresponding post-primary protocol. Sections were
Figure 1 Prostanoid biosynthesis and signalling pathways. Arachi-
donic acid (AA) is converted by PTGS1 and PTGS2 to PGG2 and
PGH2. PGH2 is then converted into one of the active prostanoids
by speciﬁc terminal synthases such as PGE synthases (PTGES,
PTGES2 and PTGES3), PGF synthases (AKR1B1 and AKR1C3),
PGD synthases (PTGDS, HPGDS), PGI synthase (PTGIS) and throm-
boxane synthase (TBXAS1). PGE2 and PGF2a may also be synthesized
by interconversion by PGF2a isomerases AKR1C1 and AKR1C2.
PGF2a may also be synthesized by conversion of PGD2 by AKR1C3
or PGE2 by CBR1. Synthesized prostanoids cross the plasma mem-
brane via a carrier mediated process and bind to their respective
cell surface receptors. Prostanoids may also be actively transported
into the cytosol for degradation to inactive metabolites (PGEM and
PGFM) by HPGD and CBR1. For abbreviations see Table I.
Expression proﬁles of the prostanoid system in the endometrium 183then counterstained in haematoxylin and mounted in pertex. Sections
were imaged using a Provis AX70 microscope (Olympus,
Southend-on-Sea, UK) and photographed using an AxioCam HRc with
AxioVision Release 4.8 (Carl Zeiss Ltd, Berlin, Germany). Immunohisto-
chemistry was performed in duplicate on three to ﬁve different endo-
metrial samples for each phase of the menstrual cycle and the most
representative section was imaged.
Statistics
Data were subjected to statistical analysis using a one-way analysis of var-
iance with Tukey’s multiple comparison post test (GraphPad Prism,
GraphPad Software, Inc., La Jolla, CA, USA).
Results
RNA transcript expression of prostanoid
enzymes across the menstrual cycle
Quantitative real-time PCR (Q-RT–PCR) was performed to deter-
mine the RNA transcriptional proﬁles of prostanoid enzymes in endo-
metrial tissue collected across the menstrual cycle. The temporal
pattern of expression for all synthase enzymes is illustrated in Fig. 2.
The analyses demonstrate that expression of prostanoid synthases
are predominantly elevated in the secretory and menstrual phases
of the cycle with a decrease in expression in the proliferative phase
(Fig. 2 and Table II).
Signiﬁcant mean fold increases in expression across the menstrual
cycle for each prostanoid enzyme are shown in Table II. The
table illustrates that expression for all prostanoid synthases, except
PTGES2, during the menstrual phase is higher by 2-fold or more com-
pared with the proliferative phase. A 10-fold or more increase in
expression was observed for PTGS1 (15.5-fold, MS versus LS),
PTGS2 (16.5-fold, Mn versus P), PTGES3 (17.1-fold, Mn versus LS),
CBR1 (10.7-fold, Mn versus P), HPGDS (12.6-fold, LS versus P) and
PTGDS (36.6-fold, MS versus Mn). The expression of HPGD, a regu-
lator of prostanoid catabolism, was signiﬁcantly decreased in the pro-
liferative and late secretory phases.
RNA transcript expression of prostanoid
receptors across the menstrual cycle
Q-RT–PCR was performed to determine the RNA transcriptional
proﬁles of prostanoid receptors in endometrial tissue collected
across the menstrual cycle. The temporal pattern of expression for
prostanoid receptors is illustrated in Fig. 3. The analysis demonstrated
that expression of the prostanoid receptors are predominantly elev-
ated in the secretory phase of the cycle except for the expression
.............................................................................................................................................................................................
Table I QPCR primer and probe sequences.
Gene symbol Forward primer Reverse primer Probe
PTGS1 (COX1), Prostaglandin-endoperoxidase
synthase 1
tgt tcg gtg tcc agt tcc aat a acc ttg aag gag tca ggc atg ag cgc aac cgc att gcc atg gag t
PTGS2 (COX2), Prostaglandin-endoperoxidase
synthase 2
cct tcc tcc tgt gcc tga tg aca atc tca ttt gaa tca gga agc t tgc ccg act ccc ttg ggt gtc a
PTGES (mPGES1), Prostaglandin E synthase cgg agg ccc cca gta ttg ggg tag atg gtc tcc atg tcg tt cga ccc gac gtg gaa cg
PTGES2 (mPGES2) Prostaglandin E synthase 2 cct cat cag caa gcg act cca ctt gtc agc agc ctc a agc agg cac cgc ctc cag
PTGES3 (mPGES3), Prostaglandin E synthase 3 Assay-on-Demand Hs01566250_gH
AKR1B1, Aldo-keto reductase 1, member B1 Assay-on-Demand Hs00739326_ml
AKR1C3, Aldo-keto reductase 1, member C1 ggg atc tca acg aga caa acg aaa gga ctg ggt cct cca aga tgg acc cga act ccc cgg tg
CBR1, Carbonyl reductase 1 ctg atc cca cac cct ttc at gct cct cct cag tga tgg tc n/a
PTGDS, Prostaglandin D2 synthase gct gca gga gaa tgg cta ct agg aag gtg gag gtc agg tt n/a
HPGD (PDGH), Hydroxyprostaglandin dehydrogenase gtg aag gcg gca tca tta tc tga atc caa cta tgc cat gc n/a
PTGIS, Prostaglandin I2 (prostacyclin) synthase acg cag atg tgg aga tcc ct gtc gtg ttc cgg ctg ca cct cag cag gta cgg ctt cgg tct g
TBXAS1, Thromboxane A synthase 1 cag gtg ttg gtt gag aac ttc agt
a
tgt cgg cta ccg act tga act caa acc cga cgc cat tct gtt ggt aaa
g
HPGDS, Haematopoietic prostaglandin D synthase Assay-on-Demand IDHs00183950_ml
PTGER1, Prostaglandin E receptor 1 aga tgg tgg gcc agc ttg t gcc acc aac acc agc att g cag cag atg cac gac acc acc atg
PTGER2, Prostaglandin E receptor 2 gac cgc tta cct gca gct gta c tga agt tgc agg cga gca cca ccc tgc tgc tgc ttc tca ttg tct
PTGER3, Prostaglandin E receptor 3 gac ggc cat tca gct tat gg ttg aag atc att ttc aac atc att atc a ctg tcg gtc tgc tgg tct ccg ctc
PTGER4, Prostaglandin E receptor 4 acg ccg cct act cct aca tg aga gga cgg tgg cga gaa t acg cgg gct tca gct cct tcc t
PTGFR, Prostaglandin F receptor gca gct gcg ctt ctt tca a cac tgt cat gaa gat tac tga aaa aaa
tac
cac aac ctg cca gac gga aaa ccg
PTGDR, Prostaglandin D2 receptor tga tga ccg tgc tct tca ct cac cgg ctc ctg tac cta ag n/a
GPR44 (CRTH2), G protein-coupled receptor 44 Assay-on-Demand, IDHs00173717_ml
PTGIR, Prostaglandin I2 receptor gcc ctc ccc ctc tac caa ttt tcc aat aac tgt ggt ttt tgt g cca aga gcc agc ccc ctt tct gc
TBXA2R, Thromboxane A2 receptor tgg tgg tgg cca gcg t cgg gtt tcg cag cac tgt tgc ccc ttc tgg tct tca tcg ccc
184 Catalano et al.Figure 2 QPCR expression analysis of prostanoid enzymes across the menstrual cycle. Relative levels of RNA transcripts were quantiﬁed by RT–
PCR from endometrial samples taken from the menstrual (Mn), proliferative (P), early secretory (ES), mid-secretory (MS) and late secretory (LS) phase
of the menstrual cycle. Expression levels were measured compared with a calibrator RNA sample. The graphs show individual values for each sample,
mean expression levels in arbitrary units normalized to 18S ribosomal RNA and error bars represent SEM. Mn (n ¼ 5), P (n ¼ 10), ES (n ¼ 10), MS
(n ¼ 10) and LS (n ¼ 10); Different letters (a–c) represent statistically signiﬁcant differences between groups (see Table II for P-values); ns, not
signiﬁcant.
Expression proﬁles of the prostanoid system in the endometrium 185of PTGFR which is signiﬁcantly elevated in the proliferative phase
(Fig. 3 and Table III).
The signiﬁcant mean fold increase in expression across the men-
strual cycle for each prostanoid receptor is shown in Table III. A dra-
matic increase in expression is observed in the proliferative phase for
PTGFR (10.3-fold, P versus Mn), in the early secretory phase
for PTGER1 (12.2-fold, ES versus Mn), in the mid-secretory phase
for PTGER2 (15.1-fold, MS versus P) and TBXR (13.0-fold, MS
versus Mn) and in the late secretory phase for PTGIR (22.3-fold, LS
versus P) and PTGDR (9.0-fold LS versus ES).
Immunohistochemical localization of
prostanoid enzymes and receptors in the
human endometrium
Immunohistochemical analysis was performed for selected genes
which have not been studied previously in the human endometrium
across the menstrual cycle. These included AKR1C3, CBR1,
AKR1B1, PTGDR and PTGER1. The analysis aimed to determine
whether the RNA transcripts detected by Q-RT–PCR were trans-
lated into protein products and to determine their spatial and tem-
poral expression across the menstrual cycle. All transcripts detected
by RT–PCR were shown to be translated into protein products
(Fig. 4). The staining intensity of the immunohistochemistry suggested
protein expression was comparable to RNA expression obtained by
Q-RT–PCR except for staining of AKR1C3 and AKR1B1 in the mid-
secretory phase and PTGER1 in the proliferative phase. These differ-
ences suggested a modest decrease in protein expression compared
with the RNA expression proﬁle, although caution must be exercised
when interpreting immunohistochemistry. Quantitatively interpreting
immunostaining between a section with intense localized staining
and a section with moderate staining intensity throughout may give
a misleading impression of differences in global expression levels.
........................................................................................
Table II Summaryof signiﬁcant increases in expression
of prostanoid enzymes across the menstrual cycle;
menstrual (Mn), proliferative (P), early secretory (ES),
mid-secretory (MS) and late secretory phase (LS).
Comparison P-value Mean fold increase
PTGS1
MS versus P P , 0.05 10.5
MS versus LS P , 0.01 15.5
PTGS2
Mn versus P P , 0.01 16.5
Mn versus MS P , 0.01 8.9
Mn versus LS P , 0.01 12.9
PTGES
LS versus P P , 0.001 6.9
LS versus ES P , 0.001 9.6
LS versus MS P , 0.01 3.3
PTGES2
MS versus LS P , 0.05 3.5
PTGES3
ES versus P P , 0.05 2.4
ES versus LS P , 0.001 4.9
MS versus P P , 0.05 2.4
MS versus LS P , 0.01 4.8
Mn versus P P , 0.001 8.5
Mn versus ES P , 0.001 3.5
Mn versus MS P , 0.001 3.6
Mn versus LS P , 0.001 17.1
AKR1B1
Mn versus P P , 0.001 3.2
Mn versus ES P , 0.01 2.6
Mn versus MS P , 0.05 2
Mn versus LS P , 0.05 2
AKR1C3
ES versus P P , 0.001 5.5
ES versus MS P , 0.01 2.2
ES versus LS P , 0.001 3.7
ES versus Mn P , 0.05 2.4
CBR1
Mn versus P P , 0.001 10.7
Mn versus ES P , 0.001 6.6
Mn versus MS P , 0.01 5.2
Mn versus LS P , 0.05 2.4
HPGDS
MS versus Mn P , 0.01 5.9
MS versus P P , 0.001 11.1
LS versus Mn P , 0.01 6.7
LS versus P P , 0.001 12.6
LS versus ES P , 0.05 2.5
Continued
........................................................................................
Table II Continued
Comparison P-value Mean fold increase
PTGDS
MS versus P P , 0.05 8.9
MS versus Mn P , 0.05 36.6
PTGIS
LS versus P P , 0.001 9.4
LS versus ES P , 0.001 5.6
LS versus MS P , 0.01 2.4
LS versus Mn P , 0.01 3.3
TBXAS1
MS versus P P , 0.001 6.1
MS versus ES P , 0.001 5.7
MS versus LS P , 0.05 2.2
HPGD
ES versus P P , 0.05 9.9
ES versus LS P , 0.05 12.6
186 Catalano et al.AKR1C3 immunostaining was localized to the glandular and luminal
epithelium and the blood vessels (Fig. 4A–E). Immunostaining was
very prominent throughout the cycle, and in the menstrual phase
(Fig. 4E) staining in the blood vessels became more prominent.
CBR1 immunostaining was localized predominantly to the glandular
and luminal epithelium (Fig. 4F–J). Staining was observed in the
stroma throughout the menstrual cycle but was faint and inconsistent.
AKR1B1 immunostaining was localized predominantly to the glandular
and luminal epithelium and the blood vessels with less intense and
scattered stromal perinuclear staining (Fig. 4K–O). In the late
secretory phase and menstrual phase (Fig. 4N and O) immunostaining
was observed in a subset of stromal cells. PTGDR immunostaining was
localized to the glandular epithelium, blood vessels and throughout the
stroma but not to all cells (Fig. 4P–T). Intense immunostaining was
observed in aggregating cells in the stroma in the secretory phase
and menstrual phase (Fig. 4S and T). PTGER1 was shown to be loca-
lized to the glandular epithelium. Immunostaining of proliferative phase
and early secretory phase (Fig. 4U and V) endometrium was weak and
conﬁned to the nuclear region. In the mid- and late secretory phases
(Fig. 4W–X) immunostaining was intense and localized predominantly
to the apical membrane of the glandular epithelium. Menstrual phase
immunostaining was faint and localized to the nuclear region of the
glandular epithelium (Fig. 4Y).
Discussion
Inﬂammatory events have been described in the human endometrium
during the period of endometrial receptivity and menstruation. These
events are characterized by an increase in endometrial capillary dilation,
permeability, stromal edema, blood ﬂow, leucocyte number and
secretion of pro-inﬂammatory factors (Fraser et al., 1987; Johannisson
et al., 1987; Peek et al., 1992). Pro-inﬂammatory enzymes PTGS1 and
PTGS2 are key mediators of these inﬂammatory processes. However,
the downstream prostanoids and receptors that contribute to these
inﬂammatory events remain unclear. The aim of this study was to
provide expression proﬁles across the menstrual cycle of the genes
which constitute the prostanoid biosynthetic and signalling pathways.
The data generated in this study are summarized in Fig. 5 and indicate
the stage of the menstrual cycle where maximum transcript expression
occurs for each gene. The data suggest that distinct components of the
Figure 3 QPCR expression analysis of prostanoid receptors across the menstrual cycle. Relative levels of RNA transcripts were quantiﬁed by RT–
PCR from endometrial samples taken from the menstrual (Mn), proliferative (P), early secretory (ES), mid-secretory (MS) and late secretory (LS) phase
of the menstrual cycle. Expression levels were measured compared with a calibrator RNA sample. The graphs show individual values for each sample,
mean expression levels in arbitrary units normalized to 18S ribosomal RNA and error bars represent SEM. Mn (n ¼ 5), P (n ¼ 10), ES (n ¼ 10), MS
(n ¼ 10) and LS (n ¼ 10); Different letters (a–c) represent statistically signiﬁcant differences between groups (see Table III for P-values); ns, not
signiﬁcant.
Expression proﬁles of the prostanoid system in the endometrium 187prostanoid system are associated with speciﬁc stages of the menstrual
cycle and expression predominantly increases from the mid-secretory
phase through to, and including, menstruation.
The proliferative phase of the menstrual cycle is characterized by
endometrial re-growth consisting of endometrial cell proliferation
and angiogenesis. This study conﬁrms that the expression of PTGFR
is maximal during the proliferative phase (Milne and Jabbour, 2003)
and therefore distinct to other components of the prostanoid biosyn-
thetic and signalling pathway. PTGFR is predominantly expressed in
the glandular epithelium and also the stromal and perivascular cells
(Milne and Jabbour, 2003). PGF2a signalling via PTGFR in endometrial
epithelial cells has been shown to induce changes in epithelial cell mor-
phology and migration (Sales et al., 2008), proliferation (Sales et al.,
2007) and angiogenesis (Keightley et al., 2010) suggesting an important
role for this receptor in tissue remodelling during endometrial
re-growth. PGF2a production in the endometrium has been shown
to rise signiﬁcantly in the mid-proliferative phase (Downie et al.,
1974). This increase may be due to the reduction of HPGD
expression at this time which would reduce PGF2a degradation.
The secretory phase is dependent on the rise in progesterone
secretion following ovulation and induces endometrial differentiation.
During the secretory phase prostanoid production continues to
increase (Downie et al., 1974), which can be accounted for by the
elevated expression of PTGS1 increasing the availability of PGH2 for
enzymatic conversion. During the early secretory phase PTGER1
expression is maximal. PTGER1 has been reported to be expressed
strongly in the luminal and glandular epithelium (Carson et al.,
2002). We demonstrate that PTGER1 immunostaining in the prolifera-
tive, early secretory and menstrual phases is localized to the nuclear
region of the glands similar to reports for PGE2 receptors 3 and 4
(Bhattacharya et al., 1998) and during the mid- and late secretory
phases localizes to the apical plasma membrane of the glands. This
suggests that PTGER1 may have two distinct functions in the endome-
trium depending on its localization. The expression of the prostanoid
receptors PTGER2, 3 and 4 peaked during the mid-secretory phase.
The increased expression of these receptors coincides with increased
stromal oedema, blood vessel permeability and endometrial blood
ﬂow in the human endometrium (Fraser et al., 1987; Johannisson
et al., 1987; Peek et al., 1992). Evidence supporting a role for PGE2
receptors in these events is demonstrated by infusion of PGE2 into
rodent uteri which has been shown to increase uterine vascular per-
meability, uterine extracellular ﬂuid volume (Hamilton and Kennedy,
1994) and act as an immunomodulator inhibiting lytic activation of
maternal leucocytes (Parhar et al., 1989).
Endometrial PGD2 release has been shown to peak during the mid-
secretory phase (Rees and Kelly, 1986) and is produced by macro-
phages and glandular epithelial cells (Norwitz et al., 1992; Norwitz
and Wilson, 2000). Two PGD2 synthases have been characterized:
lipocalin type (PTGDS) (Tanaka et al., 1997) and haematopoietic
PGDS (HPGDS). The peak in PTGDS expression in the mid-secretory
phase supports data demonstrating PTGDS to be regulated by pro-
gesterone, as expression decreases in the endometrium after adminis-
tration of mifepristone (Catalano et al., 2007). The expression of
HPGDS also peaked in the mid-secretory phase and was maintained
throughout the late secretory phase. PGD2 is involved in multiple
aspects of inﬂammation through its dual receptor systems, PTGDR
and GPR44 (previously known as CRTH2). GPR44 is a chemo-
attractant receptor expressed on T-helper (Th) and T-cytotoxic
(Tc) 2 cells, eosinophils and basophils (Nagata et al., 1999; Tsuda
et al., 2001). PTGDR expressed on dendritic cells has been shown
to inhibit T cell migration (Gosset et al., 2005). In the endometrium
PGD2 through its two receptors regulates recruitment of Th2 and
Tc2 cells into the implantation site (Michimata et al., 2002) and posi-
tively regulates trophoblast invasion (Chaouat et al., 1988). GPR44
expression levels were low and did not change throughout the men-
strual cycle, whereas PTGDR expression increased from the mid-
secretory to the menstrual phase. Immunostaining of PTGDR during
the late secretory phase and menstrual phase was detected in cell
aggregates in the stroma. This observation may reﬂect the inﬂux of
immune cells into the endometrium at these stages (Salamonsen
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Table III Summary of signiﬁcant increases in
expression of prostanoid receptors across the
menstrual cycle; menstrual (Mn), proliferative (P),
early secretory (ES), mid-secretory (MS) and late
secretory phase (LS).
Comparison P-value Mean fold increase
PTGER1
ES versus LS P , 0.001 3.8
ES versus Mn P , 0.001 12.2
PTGER2
MS versus P P , 0.001 15.1
MS versus ES P , 0.001 7.3
MS versus LS P , 0.001 2.6
MS versus Mn P , 0.001 7
PTGER3
MS versus P P , 0.05 2.2
MS versus ES P , 0.01 2.4
MS versus LS P , 0.05 2.3
MS versus Mn P , 0.05 2.9
PTGER4
MS versus P P , 0.001 2.2
MS versus ES P , 0.001 2.4
MS versus Mn P , 0.01 1.9
LS versus ES P , 0.05 1.9
PTGFR
P versus LS P , 0.01 5.8
P versus Mn P , 0.05 10.3
PTGDR
LS versus ES P , 0.05 9
PTGIR
LS versus P P , 0.001 22.3
LS versus ES P , 0.001 11.1
LS versus MS P , 0.01 6.8
TBXA2R
ES versus Mn P , 0.05 9.4
MS versus Mn P , 0.001 13
LS versus Mn P , 0.001 12.7
188 Catalano et al.and Lathbury, 2000) as dentritic cells, macrophages and natural killer
cells have been shown to express PTGDR (Chen et al., 2007;
Tajima et al., 2008). Immunostaining for PTGDR also localized to
the blood vessels. This suggests PGD2 may regulate menstrual blood
loss during menstruation via known functions of PGD2 on platelets
and blood vessels, such as increasing blood ﬂow and inhibiting platelet
aggregation and smooth muscle contraction and relaxation (Braun and
Schror, 1992; Foley et al., 2001).
Our data also demonstrate a role for thromboxane during the
secretory phase. TBXAS1 expression peaked during the mid-
secretory phase and TBXA2R expression was elevated throughout
the secretory phase. TXA2 is classically known to cause platelet aggre-
gation and constriction of blood vessels and in the endometrium pre-
sumed to regulate blood ﬂow (Swanson et al., 1992). TXA2 has also
been described to have other functions such as the regulation of angio-
genesis, but this has not been investigated in the endometrium
(Cathcart et al., 2010). TBXAS1 immunostaining has been observed in
glandular epithelium, stroma and blood vessels and increased in the
glandular epithelium during the secretory phase (Swanson et al., 1992).
In the late secretory phase in a non-pregnant cycle the corpus
luteum involutes and progesterone levels decline, triggering menstrua-
tion. The menstrual phase is characterized by ischaemia due to
Figure 4 Immunohistochemical localization of AKR1C3 (A–E), CBR1 (F–J), AKR1B1 (K–O), PTGDR (P–T) and PTGER1 (U–Y) in the endo-
metrium across the menstrual cycle; proliferative endometrium (A, F, K, P, U), early-secretory endometrium (B, G, L, Q, V), mid-secretory endome-
trium (C, H, M, R, W), late secretory endometrium (D, I, N, S, X) and menstrual endometrium (E, J, O, T, Y). Negative controls (2ve). For
abbreviations see Table I.
Expression proﬁles of the prostanoid system in the endometrium 189vasoconstriction of endometrial vessels, rupture of the capillaries initi-
ating bleeding and the consequent shedding of the functional layer of
the endometrium. During the late secretory and menstrual phases
PGF2a, PGE2, TXA2 and PGI2 production rises signiﬁcantly (Downie
et al., 1974; Liggins et al., 1980; Goodfellow et al., 1982). Our
results from the expression analysis of the prostanoid enzymes
provide data on how the production of PGF2a and PGE2 are regulated.
The production of PGE2 is regulated by different synthases predomi-
nating during the menstrual cycle with PTGES2 during the mid-
secretory phase, PTGES during the late secretory phase and
PTGES3 during the menstrual phase. This may reﬂect a mechanism
by which PGE2 production in the endometrium may be maintained
under different regulatory conditions. Classically the role of PGF2a
via PTGFR during the menstrual stage is to mediate vasoconstriction
of the endometrial vessels and contraction of the smooth muscles
of the myometrium. Evidence supporting the functionality of the
potential PGF2a synthases (AKR1B1, AKR1C1, AKR1C2, AKR1C3
and CBR1) in the human endometrium has only been demonstrated
for AKR1B1 (Chapdelaine et al., 2006), AKR1C3 and CBR1 (Kruger
and Schlegel, 1986; Pelletier et al., 1999) therefore only these genes
were analysed in this study. The rise in both PGF2a and PGE2 menstru-
ally reﬂects the signiﬁcant increase in PTGS2 and the terminal prosta-
noid synthases AKR1B1, CBR1 and PTGES3. The immuno-localization
of CBR1, AKR1C3 and AKR1B1 are predominantly in the glandular
epithelium and vasculature of the endometrium. This is in agreement
with previous studies which report glandular epithelial cells to produce
more PGF2a than stromal cells (Lumsden et al., 1984). AKR1C3
immunoreactivity has previously been shown in the luminal and gland-
ular epithelium (Pelletier et al., 1999). We also demonstrate AKR1B1
immunoreactivity in a subset of stromal cells in the late and menstrual
phases. Immunostaining for AKR1B1 localized to the perinuclear
region in stromal cells. Terminal prostanoid synthases show distinct
functional coupling with upstream COX isoxymes (Ueno et al.,
2005). The immunostaining supports previous data (Chapdelaine
et al., 2006) suggesting that AKR1B1 couples to PTGS2 which
resides predominantly in the perinuclear membranes.
PGI2 is the main prostanoid synthesized by the vascular endo-
thelium and it causes blood vessel dilatation and inhibition of platelet
aggregation (Smyth and FitzGerald, 2002): these effects have
suggested a role for PGI2 in menstruation. PTGIS and PTGIR immuno-
reactivity in the endometrium is localized predominantly to the gland-
ular and luminal epithelium with expression also detected in the
vasculature and stroma (Battersby et al., 2004). PGI2 has been
shown to be inhibited by progesterone (Levin et al., 1992) which cor-
relates with the expression of PGIS peaking in the late secretory phase
as progesterone is withdrawn. PTGIR with a similar expression proﬁle
has also been demonstrated to be inhibited by progesterone as
expression increases in the endometrium after administration of mife-
pristone (Catalano et al., 2007).
This study represents the ﬁrst comprehensive view of prostanoid
action in the endometrium during the menstrual cycle. Identifying
the expression proﬁle of the prostanoid system and its association
to key inﬂammatory events provides valuable insight into the role of
speciﬁc signalling pathways in normal endometrial function. Menstrual
cycle disorders such as primary dysmenorrhea and heavy menstrual
blood loss in the absence of any pathology have been associated
with an increase and an imbalance in prostanoid synthesis (Lundstrom
and Green, 1978; Smith et al., 1981; Makarainen and Ylikorkala, 1986).
Hence the data presented herein provides the potential to identify
which component(s) of the prostanoid system may contribute to
Figure 5 Expression of prostanoid biosynthetic enzyme and receptor genes in the menstrual cycle. Summary diagram illustrating the maximal
expression during the menstrual cycle for each prostanoid biosynthesis and receptor gene analysed and reported maximum production during the
menstrual cycle for each prostanoid (shown in red). WOI, window of implantation. For abbreviations see Table I.
190 Catalano et al.inﬂammatory-associated disorders of the endometrium such as heavy
menstrual blood loss and dysmenorrhoea and may aid in the develop-
ment of novel therapeutics.
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